1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

Cinquil is a humanized mAb targeting IL-5, a cytokine that regulates the activation of eosinophils. Teva added Cinquil to its portfolio as part of the Cephalon acquisition in 2011. Cinquil is currently being studied in both eosinophilic esophagitis and asthma. The importance of eosinophilic airway inflammation, which is present in 40- 60% of the severe asthmatic population, is evidenced by the number of companies targeting this patient segment. Of all the products in the pipeline that lead to eosinophil depletion, the most advanced ones target the IL-5 pathway.

Scope

- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Cinquil including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Cinquil for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Cinquil performance
- Obtain sales forecast for Cinquil from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table Of Contents

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.1.3 Prognosis 16
3.1.4 Quality of Life 16
3.2 Symptoms 17
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Diagnosis 18
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 19
4.1.3 Clinical Practice 21
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 28
6 Unmet Need and Opportunity 32
6.1 Overview 32
6.2 Personalized Therapies to Control Severe Asthma 33
6.2.1 Unmet Need 33
6.2.2 Gap Analysis 34
6.2.3 Opportunity 34
6.3 Better Patient Compliance 34
6.3.1 Unmet Need 34
6.3.2 Gap Analysis 35
6.3.3 Opportunity 36
6.4 Lower Cost of Asthma Medications 36
6.4.1 Unmet Need 36
6.4.2 Gap Analysis 37
6.4.3 Opportunity 37
6.5 Proper Diagnosis of Asthma in Children 37
6.5.1 Unmet Need 37
6.5.2 Gap Analysis 38
6.5.3 Opportunity 38
7 Pipeline Assessment 39
7.1 Overview 39
7.2 Promising Drugs in Clinical Development 41
8 Cinquil (reslizumab) 43
8.1 Overview 43
8.2 Efficacy 44
8.3 Safety 45
8.4 Dosing and Formulation 45
8.5 Potential Clinical Positioning 45
8.6 Potential Commercial Positioning 46
8.7 Pricing and Reimbursement 46
8.8 SWOT Analysis 47
8.9 Forecast 47
9 Appendix 49
9.1 Bibliography 49
9.2 Abbreviations 54
9.3 Methodology 56
9.4 Forecasting Methodology 56
9.4.1 Diagnosed Asthma Patients 56
9.4.2 Percent Drug-Treated Patients 57
9.4.3 General Pricing Assumptions 57
9.4.4 Generic Erosion 58
9.4.5 Pricing of Pipeline Agents 58
9.5 Physicians and Specialists Included in This Study 59
9.6 About the Authors 62
9.6.1 Author 62
9.6.2 Author/Reviewer 62
9.6.3 Reviewer 63
9.6.4 Global Head of Healthcare 64
9.7 About GlobalData 65
9.8 Disclaimer 65

1.1 List of Tables

Table 1: Symptoms of Asthma 17
Table 2: Treatment Guidelines for Asthma by Country 19
Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013 20
Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency 23
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age 25
Table 6: Leading Treatments for Asthma, 2014 31
Table 7: Unmet Need and Opportunity in Asthma 32
Table 8: Asthma - Late Stage Pipeline, 2014 41
Table 9: Product Profile - Cinquil 44
Table 10: Efficacy of Cinquil Versus Placebo 44
Table 11: Cinquil's Safety Profile 45
Table 12: Cinquil SWOT Analysis, 2014 47
Table 13: Global Sales Forecast ($) for Cinquil, 2013-2023 48
Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 61

1.2 List of Figures

Figure 1:Stepwise Disease Management Approach for Asthma in Adults 22
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger 24
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023 42

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.